Information  X 
Enter a valid email address

Mereo BioPharma Grp (MPH)

  Print   

Thursday 15 August, 2019

Mereo BioPharma Grp

PDMR Shareholding

RNS Number : 2441J
Mereo BioPharma Group plc
15 August 2019
 

Mereo BioPharma Group plc

 

 ("Mereo" or the "Company")

 

Notification of PDMR Dealing

 

London, August 15, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on August 13, 2019, Charles Sermon, General Counsel, purchased 590 American Depositary Shares (ADSs) at a price of USD3.09 per ADS. On August 14, 2019, Charles purchased 754 ADSs at a price of USD3.11 per ADS.

 

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Charles Sermon

 

2

Reason for the notification

a)

Position/status

General Counsel

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

 

b)

Nature of the transaction

PURCHASE OF ADS

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD 3.09

590

 

 

d)

Aggregated information:  volume, Price

Aggregated volume: 590

Aggregated price: USD3.087

e)

Date of the transaction

2019-08-13

f)

Place of the transaction

XNMS

 

 

1

Details of the person discharging managerial responsibilities

 

a)

Name

Charles Sermon

 

2

Reason for the notification

a)

Position/status

General Counsel

 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

 

b)

LEI

213800U8JQHIJOS5AS09

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

 

b)

Nature of the transaction

PURCHASE of ADS

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

USD3.11

754

 

 

d)

Aggregated information:  volume, Price

Aggregated volume: 754

Aggregated price: GBP3.105

e)

Date of the transaction

2019-08-14

f)

Place of the transaction

XNMS

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHBUGDIIUBBGCU

a d v e r t i s e m e n t